Literature DB >> 3493224

High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas.

S Ozawa, M Ueda, N Ando, O Abe, N Shimizu.   

Abstract

EGF receptor levels were investigated in esophageal squamous-cell carcinoma tissues from 31 patients. Twenty-two (71%) of these cancer tissues exhibited significantly higher 125I-EGF binding activity than normal mucosa in the adjacent non-cancerous tissues. These EGF receptor levels were then compared on the basis of pathological findings including lymph-node metastasis, depth of invasion, differentiation type, vascular invasion, infiltration and location of the lesion. Unlike previous reports on breast and bladder cancers, our study showed no obvious correlation between these pathological characteristics and the EGF receptor levels in esophageal carcinomas. Immunohistochemical staining with the anti-EGF receptor monoclonal antibody detected EGF receptors in squamous cells of the cancer tissues as well as in the basal cells of nearby normal epithelium. Since the basal cells have proliferative potential in the esophagus, the increase in EGF receptor levels in these cells may possibly be associated with the development of human esophageal squamous-cell cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493224     DOI: 10.1002/ijc.2910390311

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  Frequent mutation of the p53 gene in human esophageal cancer.

Authors:  M C Hollstein; R A Metcalf; J A Welsh; R Montesano; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Expression of human epidermal growth factor and its receptor in esophageal cancer.

Authors:  H Mukaida; T Yamamoto; T Hirai; M Toi; T Nakamura; T Wada; Y Yamashita; K Kawano; M Niimoto
Journal:  Jpn J Surg       Date:  1990-05

3.  Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor.

Authors:  E Aboud-Pirak; E Hurwitz; F Bellot; J Schlessinger; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Epidermal growth factor receptors in the oesophagus.

Authors:  J Jankowski; S Murphy; G Coghill; A Grant; K G Wormsley; D S Sanders; M Kerr; D Hopwood
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

5.  Association between epidermal growth factor polymorphism and esophageal squamous cell carcinoma susceptibility.

Authors:  Lin Cui; Xin-Min Pan; Chun-Fen Ma; Jun Shang-Guan; Hai-Bin Yu; Guang-Xue Chen; Jia Wang
Journal:  Dig Dis Sci       Date:  2009-01-27       Impact factor: 3.199

6.  Conversion of epidermal growth factor (EGF) into a stimulatory ligand for A431-cell growth by herbimycin A by decreasing the level of expression of EGF receptor.

Authors:  Y Murakami; H Fukazawa; S Mizuno; Y Uehara
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

7.  Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells.

Authors:  Y Murakami; S Mizuno; Y Uehara
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

8.  Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique.

Authors:  Y Wang; S Minoshima; N Shimizu
Journal:  Jpn J Hum Genet       Date:  1993-12

9.  Correlation between epidermal growth factor receptor concentration and the growth of human gastric cancer xenografts in nude mice.

Authors:  T Kiyama; M Onda; A Tokunaga; I Fujita; T Okuda; T Mizutani; T Yoshiyuki; Y Shimizu; K Nishi; N Matsukura
Journal:  Gastroenterol Jpn       Date:  1992-08

10.  Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site.

Authors:  R Pellegrini; F Centis; S Martignone; A Mastroianni; E Tagliabue; E Tosi; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.